Comparison of efficacy of low glycemic index treatment and modified Atkins diet among children with drug-resistant epilepsy: A randomized non-inferiority trial
- PMID: 39887979
- DOI: 10.1111/epi.18292
Comparison of efficacy of low glycemic index treatment and modified Atkins diet among children with drug-resistant epilepsy: A randomized non-inferiority trial
Abstract
Objective: The ketogenic diet has been the mainstay of treatment of drug-resistant epilepsy (DRE). No comparative trials have been conducted to assess the efficacy of the two less strict ketogenic diets: modified Atkins diet (MAD) and low glycemic index treatment (LGIT). This study assesses the non-inferiority of LGIT compared with MAD.
Methods: This was an open-label randomized non-inferiority trial. Children with DRE were randomized to receive either MAD or LGIT as an add-on to anti-seizure medications. The primary endpoint was percentage seizure reduction at the end of 24 weeks of therapy compared to the baseline. The non-inferiority margin of -15% was predefined to calculate the sample size.
Results: Ninety-one children were enrolled and randomized to receive either MAD (n = 45) or LGIT (n = 46). Intention-to-treat analysis done at the end of 24 weeks of therapy showed a mean (±standard deviation [SD]) percentage seizure reduction of 60.7% (±41.3) in the MAD sub-group and 57% (±39.4) in the LGIT sub-group (p = 0.664). The absolute difference between the means of percentage seizure reduction was -3.7 (-20.5 to 13.2) and crossed the non-inferiority margin. Ten children in the MAD group and nine children in the LGIT group did not complete 24 weeks of therapy. Adverse effects were comparable between the arms (MAD, 66.6%; LGIT, 50%), although serious adverse effects were higher in the MAD arm. The most common adverse effect was decreased acceptance (24.2%) followed by decreased satiety (9.9%), vomiting (9.9%), weight loss (5.5%), constipation (5.5%), and diarrhea (3.3%). Dyslipidemia was more commonly seen in the MAD group (MAD, six; LGIT, one). One death in the LGIT arm was unrelated to therapy. Although there was no statistically significant difference in improvement in cognition, behavior, and quality of life scales, improvement was noted from baseline scores.
Significance: LGIT may be non-inferior to MAD in the treatment of children with DRE with the advantage of increased acceptance and fewer adverse effects.
Keywords: drug resistant epilepsy; ketogenic diet; low glycemic index treatment; modified atkins diet.
© 2025 International League Against Epilepsy.
Similar articles
-
Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial.JAMA Pediatr. 2020 Oct 1;174(10):944-951. doi: 10.1001/jamapediatrics.2020.2282. JAMA Pediatr. 2020. PMID: 32761191 Free PMC article.
-
Ketogenic diets for drug-resistant epilepsy.Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903. doi: 10.1002/14651858.CD001903.pub5. Cochrane Database Syst Rev. 2020. PMID: 32588435 Free PMC article.
-
Modified Atkins Diet vs Low Glycemic Index Treatment for Drug-Resistant Epilepsy in Children: An Open Label, Randomized Controlled Trial.Indian Pediatr. 2021 Sep 15;58(9):815-819. Epub 2021 Feb 25. Indian Pediatr. 2021. PMID: 33634794 Clinical Trial.
-
Efficacy of low glycemic index diet therapy (LGIT) in children aged 2-8 years with drug-resistant epilepsy: A randomized controlled trial.Epilepsy Res. 2021 Mar;171:106574. doi: 10.1016/j.eplepsyres.2021.106574. Epub 2021 Feb 9. Epilepsy Res. 2021. PMID: 33582533 Clinical Trial.
-
Ketogenic diets for drug-resistant epilepsy.Cochrane Database Syst Rev. 2018 Nov 7;11(11):CD001903. doi: 10.1002/14651858.CD001903.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Jun 24;6:CD001903. doi: 10.1002/14651858.CD001903.pub5. PMID: 30403286 Free PMC article. Updated.
References
REFERENCES
-
- Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42:1255–1260.
-
- Guery D, Rheims S. Clinical management of drug resistant epilepsy: a review on current strategies. Neuropsychiatr Dis Treat. 2021;17:2229–2242. https://doi.org/10.2147/NDT.S256699
-
- Auvin S. Non‐pharmacological medical treatment in pediatric epilepsies. Rev Neurol (Paris). 2016;172:182–185. https://doi.org/10.1016/j.neurol.2015.12.009
-
- Hatoum R, Nathoo‐Khedri N, Shlobin NA, Wang A, Weil AG, Fallah A. Barriers to epilepsy surgery in pediatric patients: a scoping review. Seizure. 2022;102:83–95. https://doi.org/10.1016/j.seizure.2022.08.013
-
- Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016;2:1–26. https://doi.org/10.1002/14651858.CD001903.pub3
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources